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The extracellular domain sequence of the hα1, α3, α4, α6, α7, α9, and α10 nAChR 
subunits were retrieved from the Uniprot database.1 Both crystal structures of Aplysia 
californica AChBP (acetylcholine binding protein) in complex with α-conotoxin 
PnIA[Α10L,D14K] (PDB code 2BR8), and the hα9 nAChR subunit extracellular 
domain (PDB code 4D01) from the Protein Data Bank, were used as templates to 
build 200 models of each α-conotoxin−nAChR complexes.2,3 Models with the lowest 
DOPE score were selected for further structural refinement using molecular dynamics 
(MD) simulations. The structures of Vc1.1 analogues, Vc1.1[D11N] and Vc1.1[PeIA], 
were generated using Modeller based on the NMR structure of Vc1.1(PDB code 
2H8S).4 
Molecular dynamics simulations 
The protonation states of His, Asp and Glu residues at the conotoxin/nAChR 
complexes were predicted using the PropKa 3.1 method.5 The receptor complexes 
were solvated in a truncated octahedral TIP3P water box containing ~10800 water 
molecules. Sodium ions were added to neutralize the systems. The systems were first 
minimized with 3,000 steps of steepest descent and then 3,000 steps of conjugate 
gradient with the solute restrained to their position by a harmonic force of 100 
kcal/mol·Å2. A second minimization was then performed but with all position 
restraints withdrawn. The systems were then gradually heated up from 50 to 300 K in 
the NVT ensemble over 100 ps with the solute restrained to their position using a 5 
kal/mol·Å2 harmonic force potential. MD simulations were then carried out in the 
NPT ensemble, and the position restraints were gradually removed over 100 ps. The 
production runs were conducted over 50 ns simulation time with pressure coupling set 
at 1 atm and a constant temperature of 300 K. The MD simulations used a time step of 
2 fs and, all bonds involving hydrogen atoms were maintained to their standard length 
using the SHAKE algorithm.6 The particle-mesh Ewald (PME) method was used to 
model long-range electrostatic interactions.7 MD trajectories were analyzed using 
VMD (http://www.ks.uiuc.edu/) and molecules were drawn using PyMol (Schrödinger, 
LLC).  
For validation of the Vc1.1 analogue stability, 100 ns repeated MD simulations 
were performed on Vc1.1[N9D] and Vc1.1[PeIA] systems respectively, using the 
same method as described above. 
Binding energy decomposition 
To quantify the binding energy contribution of these key residues in the ligand 
binding site, binding energy decomposition was carried out using the MMPBSA.py 
script in AMBER16.8 The binding free energy (ΔGbinding) values were calculated using 
the following equation: 
ΔGbinding = Gcomplex – Gligand – Greceptor (1) 
where the binding free energy (ΔGbinding) was determined using MMGB/SA method.9 
This method was identified in our previous study as being slightly more efficient for 
ranking mutational energies based on homology models than the MMPB/SA method. 
Details of the MMGB/SA method on peptide binding energy calculation was 




Briefly, Vc1.1[D11N] and Vc1.1[PeIA] were assembled on rink amide 
methylbenzhydrylamine resin (Novabiochem) using solid-phase peptide synthesis 
with a neutralization/2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate activation procedure for Fmoc (N-(9-fluorenyl)methoxycarbonyl) 
chemistry. Cleavage was achieved by treatment with 88:5:5:2 ratio of trifluoroacetic 
acid (TFA), phenol, water and triisopropylsilane as scavengers, at room temperature 
(20−25 °C) for 2 h. TFA was evaporated at low pressure in a rotary evaporator. 
Peptides were precipitated with ice-cold ether, filtered, dissolved in 50% buffer A/B 
(buffer A consists of 99.95% H2O/ 0.05% TFA and buffer B consists of 90% 
CH3CN/10% H2O/0.045% TFA), and lyophilized. Crude peptides were purified by 
RP-HPLC on a Phenomenex C18 column, and its molecular mass was confirmed using 
electrospray mass spectrometry before they were pooled and lyophilized for oxidation. 
The four cystines in the peptides were selectively oxidized in two steps. In the first 
step the non-protected cystines were oxidized in 0.1 M NH4HCO3 (pH 8–8.5) at a 
concentration of 0.5 mg/ml, and stirred at room temperature overnight. In the second 
step, the Acm-protected cystines were oxidized by dissolving the peptides in iodine 
solution filled at concentration of 1 mg/ml, and stirred for 30 min. Ascorbic acid was 
then added to stop the oxidizing reaction and the solution was stirred again until no 
colour was visible. After two rounds of oxidation, peptides were purified by 
RP-HPLC and their mass (Figure S7) and purity (Figure S8) were validated using 
electrospray-mass spectrometry (MS) and analytical RP-HPLC, respectively. 
Circular dichroism (CD) study 
CD spectra were performed on Jasco J-810 spectropolarimeter over the wavelength 
range of 250-190 nm using a 1.0 mm path length cell, a bandwidth of 1.0 nm, a 
response time of 2 s, and averaging over three scans. Spectra were recorded at room 
temperature under nitrogen atmosphere. Peptides were dissolved in buffer A and 
buffer B. The concentration of Vc1.1, Vc1.1[D11N], Vc1.1[PeIA], and PeIA was 0.28 
mM, 0.28 mM, 0.29 mM and 0.30 mM, respectively. The spectra are expressed as 
molar ellipticity ([θ])·[θ] = 1000·mdeg/(l·c) where, mdeg is the raw CD data, c is the 
peptide molar concentration (mM), and l is cell path length (mm). 
Oocyte preparation and microinjection 
All procedures were approved by the University of Sydney Animal Ethics 
Committee (project number 2016/970). Stage V-VI oocytes (Dumont’s classification; 
1200-1300 μm diameter) were obtained from Xenopus laevis, defolliculated with 1.5 
mg/ml collagenase Type II (Worthington Biochemical Corp., Lakewood, NJ) at room 
temperature for 1-2 h in OR-2 solution containing (in mM) 82.5 NaCl, 2 KCl, 1 
MgCl2 and 5 HEPES at pH 7.4. Oocytes were injected with 35 ng cRNA for hα9α10 
nAChR (concentration confirmed spectrophotometrically and by gel electrophoresis) 
at α9:α10 subunit mRNA ratios of 1:1. 1:3 and 3:1, using glass pipettes pulled from 
glass capillaries (3-000-203 GX, Drummond Scientific Co., Broomall, PA, USA). 
Oocytes were incubated at 18 ºC in sterile ND96 solution composed of (in mM) 96 
NaCl, 2 KCl, 1 CaCl2, 1 MgCl2 and 5 HEPES at pH 7.4, supplemented with 5% FBS, 
50 mg/L gentamicin (GIBCO, Grand Island, NY, USA) and 10000 U/mL 
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penicillin-streptomycin (GIBCO, Grand Island, NY, USA). 
Oocyte two-electrode voltage clamp recording and data analysis 
Voltage-recording and current-injecting electrodes were pulled from GC150T-7.5 
borosilicate glass (Harvard Apparatus, Holliston, MA) and filled with 3 M KCl giving 
resistances of 0.3–1 MΩ. 
Oocytes were incubated in 100 µM BAPTA-AM ~3 h before recording and perfused 
with ND115 solution containing (in mM): 115 NaCl, 2.5 KCl, 1.8 CaCl2, and 10 
HEPES at pH 7.4 using a continuous Legato 270 push/pull syringe pump perfusion 
system (KD Scientific, Holliston, MA, USA) at a rate of 2 mL/min in an OPC-1 
perfusion chamber of < 20 µL volume (Automate Scientific, Berkeley, CA, USA). 
Due to the Ca2+ permeability of hα9α10 nAChRs, BAPTA-AM incubation was carried 
out to prevent the activation of X. laevis oocyte endogenous Ca2+-activated chloride 
channels. 
Initially, oocytes were briefly washed with ND115 solution followed by 3 
applications of acetylcholine (ACh) at a half-maximal excitatory ACh concentration 
(EC50) for hα9α10 nAChRs. Washout with bath solution was done for 3 min between 
ACh applications. Oocytes were incubated with peptides for 5 min with the perfusion 
system turned off, followed by co-application of ACh and peptide with flowing bath 
solution. All peptide solutions were prepared in ND115 + 0.1 % bovine serum 
albumin. Peak current amplitudes before (ACh alone) and after (ACh + peptide) 
peptide incubation were measured using Clampfit version 10.7.0.3 software 
(Molecular Devices, Sunnyvale, CA, USA), where the ratio of ACh + peptide-evoked 
current amplitude to ACh alone-evoked current amplitude was used to assess the 
activity of the peptides at hα9α10 nAChRs. All electrophysiological data were pooled 
(n = 3-16) and represent means ± standard error of the mean (SEM). Data analysis 
was performed using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). 
ACh EC50 and α-conotoxin IC50 values were determined from concentration-response 
relationships fitted to a non-linear regression function and reported with error of the fit. 
Data sets were compared using Tukey’s test. Differences were regarded statistically 
significant when p < 0.05. 
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 Table S1. Quantitative analysis of the purity of the peptide. 
Name Retention time 
(min) 
Peak area Total peak area Purity 
Vc1.1[D11N] 21.773 2329446 2382506 97.8% 
Vc1.1[PeIA] 12.847 18474014 18791063 98.3% 
PeIA 23.307 4330976 4557830 95.0% 
RgIA# 15.860 4267319 4437735 96.16% 
Vc1.1 22.053 2754800 2898800 95.03% 
The purity of the peptide was analysed using analytical RP-HPLC at a flow rate of 1 
mL/min with the concentration of the buffer B increased from 5% to 100% with a 





Figure S1. Activity of the α-conotoxins Vc1.1, RgIA#, and PeIA at the human 
α9α10 nAChR. Concentration-response relationships of relative ACh-evoked current 
amplitude mediated by hα9α10 nAChR at hα9 to hα10 subunit 1:1 ratio in the 
presence of Vc1.1, PeIA, and RgIA# (0.1 nM – 30 μM) giving IC50 values of 1.0 ± 0.1 
µM, 22.2 ± 1.6 nM and 248.7 ± 19.2 nM, respectively (mean ± SEM, n = 5-16). 





Figure S2. Internal backbone H-bond between PeIA residues H5 and C8. Stability 
in the distance between N atom of His5 and H atom of Cys8 (H5&N—C8&H) in 




Figure S3. Side chain energetic contribution to the α-conotoxin’s binding affinity. 
(A-C) Side chain-energetic contribution for residues at the principal components of 
S9 
 
the α10(+)-α9(−) (blue) and α9(+)-α9(−) (red) interfaces to the binding affinity of 
Vc1.1, RgIA#, and PeIA, respectively. Non-conserved residues from the α9 subunit 
are labelled red. Side chain energetic contribution of the α9 and α10 subunit residues 















Figure S4. Activity of α-conotoxins at human α9α10 and α9[N154G]α10 nAChRs 
expressed from varied α9:α10 mRNA ratios. (A) ACh concentration-response 
relationship obtained for relative ACh-evoked current amplitude mediated by hα9α10 
nAChRs (mean ± SEM, n = 3-6) at varying hα9 to hα10 subunit ratios. EC50 values 
are given in Table 1. Concentration-response relationships for the inhibition of 
relative ACh-evoked current amplitude mediated by hα9α10 nAChRs (mean ± SEM, 
n = 3-16) at varying hα9 to hα10 subunit ratios in the presence of (B) Vc1.1, (C) 
Vc1.1[D11N], and (D) Vc1.1[PeIA]. IC50 values are given in Table 1. Whole-cell 
hα9α10 nAChR-mediated currents at 1:3 and 3:1 ratios were activated by 50 μM and 
30 μM ACh, respectively, whole-cell hα9[N154G]α10 nAChR-mediated currents at 
1:3 and 3:1 ratios were activated by 20 μM and 30 μM ACh, respectively and 
whole-cell hα9α10[G154N] nAChR-mediated currents at 1:3 ratios were activated by 
60 μM ACh (close to their respective EC50 values). 
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Figure S5. Structural comparison of wild-type Vc1.1 and analogues Vc1.1[D11N] 
and Vc1.1[PeIA]. RMSD (root mean square deviation) for the backbone atoms of (A) 
Vc1.1 (black) vs Vc1.1[D11N] (red and green), and (B) Vc1.1 vs Vc1.1[PeIA] (red 
and green). Structural comparison of (C) Vc1.1 (grey) vs Vc1.1[D11N] (blue), and (D) 





Figure S6. Spectroscopic comparison of wild-type Vc1.1 and analogues 
Vc1.1[D11N] and Vc1.1[PeIA]. Circular dichroism spectra of Vc1.1 (black), 










Figure S8. Analytical RP-HPLC profiles of Vc1.1, Vc1.1[D11N], Vc1.1[PeIA], 
PeIA, and RgIA#.  
 
